Aeglea BioTherapeutics Inc AGLE

NAS: AGLE | ISIN: US00773J1034   29/01/2024
27,66 USD (+0,58%)
(+0,58%)   29/01/2024

9 november 2023 · Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

3 november 2023 · Aeglea BioTherapeutics Announces Grants of Inducement Awards · Persbericht

1 november 2023 · SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE) · Persbericht

31 oktober 2023 · Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences · Persbericht

3 oktober 2023 · Aeglea BioTherapeutics Announces Grants of Inducement Awards · Persbericht

14 september 2023 · Aeglea BioTherapeutics to Participate in Upcoming September Conference · Persbericht

7 september 2023 · Aeglea BioTherapeutics Announces Reverse Stock Split · Persbericht

5 september 2023 · Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones · Persbericht

11 augustus 2023 · Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results · Persbericht

27 juli 2023 · Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma · Persbericht

23 juni 2023 · Aeglea BioTherapeutics Announces Grant of Inducement Awards · Persbericht

22 juni 2023 · Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics · Persbericht

11 mei 2023 · Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results · Persbericht

12 april 2023 · Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives · Persbericht

17 maart 2023 · Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 maart 2023 · Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates · Persbericht

6 januari 2023 · Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency · Persbericht

2 december 2022 · Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

30 november 2022 · Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer · Persbericht

15 november 2022 · Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer · Persbericht

Mijn selecties